Revolution Medicines, Inc. (RVMD)
NEUTRALFundamental
36
मूल्य
$211.13
मार्केट कैप
$44.23B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
0
31/12/2025 को समाप्त वित्त वर्ष
शुद्ध आय
$-1.13B
31/12/2025 को समाप्त वित्त वर्ष
Free Cash Flow
$-914M
कुल इक्विटी
$1.63B
कुल देनदारियाँ
$723M
Current Ratio
11.38
Interest Coverage
27.42
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$223.24
वर्तमान मूल्य
$211.13
Margin of Safety
+5.4%
Fair Value सीमा
$212.07 - $234.40
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-69.3%
P/B Ratio
17.40
P/FCF
-
Gross Margin
-
ROIC
-32.4%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-32.4%
WACC
12.0%
ROIC − WACC
-44.4 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (7)
- EPS shows upward trend
- Price CAGR 32.01%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 93% Buy
फेल (10)
- ROIC -32.4%
- P/B Ratio 17.40
- Operating Margin -Infinity%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -54.1%
- Earnings Surprise avg -25.1%
- Share Dilution 13.4%
- Piotroski F-Score 1/9
अनुपलब्ध (10)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman | 63 |
| Mr. Jack Anders | Chief Financial Officer | 48 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 62 |
| Mr. Jeffrey Cislini J.D. | Senior VP, General Counsel & Corporate Secretary | 50 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor | 64 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | - |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | 44 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | - |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | - |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | - |
Audit जोखिम
2
बोर्ड जोखिम
8
मुआवजा जोखिम
8
शेयरधारक अधिकार जोखिम
8
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for RVMD, sourced from Markets Gazette.
- 6/1/2026POSITIVERevolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines announced a significant breakthrough in pancreatic cancer treatment, with its experimental pill demonstrating a doubling of patient survival rates and a 60% reduction in the risk of death during clinical trials. This development is particularly noteworthy given the historically poor prognosis associated with pancreatic cancer. The positive trial results suggest a potential paradigm shift in treatment options for this aggressive disease. For investors, this news could translate into substantial future revenue streams and a re-evaluation of the company's growth prospects, especially as the stock is currently trading near its all-time highs.
- 4/13/2026POSITIVERevolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo
Revolution Medicines Inc. stock surged following promising Phase 3 trial results for its pancreatic cancer drug, darsonvalrasib. The study demonstrated a doubling of survival rates compared to standard chemotherapy, a significant breakthrough for patients with KRAS G12C-mutated pancreatic cancer. The company announced plans for regulatory filings, signaling a clear path toward potential market approval. This development is highly encouraging for investors, suggesting a strong future revenue stream and a significant advancement in oncology treatment.
- 2/25/2026NEUTRALRevolution Medicines (RVMD) Earnings Transcript
Revolution Medicines (RVMD) has released its earnings transcript, although the specific content is not yet available for analysis. Investors are keenly awaiting the details of this publication, which could provide clarity on the company's financial performance and future outlook. The absence of immediate information prevents a directional assessment, keeping the stock in a holding pattern. It will be crucial to monitor the data as soon as it is disclosed to understand the impact on research and development, product pipeline, and market strategies, which are fundamental elements for evaluating RVMD's growth potential in the biopharmaceutical sector.
via Markets Gazette